结直肠癌患者血清中可溶性CD44v9的含量及其临床意义

为探讨结直肠癌患者血清中可溶性CD44v9的含量及其临床意义,本研究应用酶联免疫吸附测定（ELISA）法检测27例结直肠癌患者、13例结肠腺瘤患者、20名正常人血清中可溶性CD44v9的含量。结果显示,结直肠癌患者血清中可溶性CD44v9含量水平明显高于正常对照组,P〈0．05;结肠腺瘤患者与正常人比较,差异无统计学意义,P〉0．05。Ⅲ＋IV期结直肠癌患者血清中可溶性CD44v9含量水平明显高于I＋Ⅱ期结直肠癌患者,P〈0．05。低分化结直肠癌、黏液腺癌患者血清中可溶性CD44v9含量水平明显高于高、中分化的结直肠癌患者,P〈0．05。结果表明,检测血清中可溶性CD44v9的含量水平对结直肠癌的诊断及预后评估具有重要意义。     

结直肠癌早期肝转移的预测

目的研究CK20 mRNA、CD44v6、血管内皮生长因子（VEGF）与结直肠癌肝转移的关系,探讨临床预测结直肠癌早期肝转移的有效的客观指标。方法应用荧光定量逆转录聚合酶链反应（RT—PCR）法检测50例结直肠癌患者回流门静脉血中CK20 mRNA,并同时应用免疫组织化学方法测定结直肠癌癌组织中CD44v6、VEGF的表达;并与良性病变对照组10例和正常组织对照组10例比较。结果结直肠癌患者门静脉血CK20 mRNA;癌组织中CD44v6、VEGF表达阳性率明显高于良性病变对照组（P〈0．01）和正常对照组（P〈0．01）;结直肠癌组织中CIM4v6及VEGF的表达与门静脉血中CK20 mRNA的表达有显著相关性（r．=0．933,r2=0．906,P〈0．05）;同时肝转移组CK20 mRNA、CD44v6、VEGF阳性表达率均高于非肝转移组（P〈0．05）。结论联合检测CD44v6、VEGF及CK20 mRNA预测结直肠癌肝转移,可提高预测的灵敏度及特异性,对于结直肠癌早期肝转移监测具有较高的临床价值。     

内镜活检组织CD44v6检测对结直肠癌转移诊断的价值

目的 探讨内镜活检组织CD44v6检测对结直肠癌转移诊断的价值。方法 采用免疫组织化学方法检测结直肠癌活检组织和对照组组织中CD44v6表达。结果 慢性结肠炎、结肠息肉、结肠腺瘤和结直肠癌活检组织中CD44v6的表达阳性率分别为10.0％、21.1％、23.2％和63.2％。结直肠癌穿破肠浆膜及转移组(Dukes分期B、C、D期)活检组织CD44v6阳性表达率为70.1％,高于无转移组36.7％(Dukes分期 A),差异具有显著性(P<0.05),癌前病变即开始逐渐出现高表达趋势。结论 CD44v6与肿瘤的转移相关,结直肠癌活检组织中CD44v6蛋白可作为一个新的预测结直肠癌转移潜能的生物学指标并在术前决策方面有很大临床价值。     

CK20mRNA、CD44v6和PCNA对大肠癌早期肝转移预测的研究

目的:研究CK20mRNA、CD44v6和PCNA与大肠癌肝转移的关系,探讨临床预测大肠癌早期肝转移的客观指标。方法:应用荧光定量RT-PCR法检测50例大肠癌患者回流门静脉血中 CK20mRNA,同时应用免疫组织化学方法测定大肠癌癌组织中CD44v6、PCNA的表达,并与对照组比较。结果:大肠癌患者门静脉血CK20mRNA、癌组织中CD44v6、PCNA表达阳性率明显高于良性病变对照组(P<0．01)和正常对照组(P<0．01);大肠癌组织中CD44v6及PCNA的表达与门静脉中 CK20mRNA的表达有显著相关性(γ1=0．933,γ2=0.906,P<0．05);肝转移组CK20mRNA、CD44v6、 PCNA阳性表达率均高于非肝转移组(P<0.05)。结论:联合检测CD44v6、PCNA及CK20mRNA预测大肠癌肝转移,可显著提高预测的灵敏度及特异性,对于大肠癌早期肝转移监测具有很高的临床价值。     

胃癌患者外周血及瘤体CD44v5的表达与转移相关性研究

目的探讨胃癌患者外周血淋巴细胞(PBL)CD44变异体5(CD44v5)含量和瘤组织CD44v5表达情况,及其对胃癌转移的诊断和进展评价的意义.方法应用流式细胞仪(FCM)检测31例胃癌患者术前PBL CD44v5含量并与正常对照组相比较,同时采用免疫组化SABC法检测33例胃癌组织CD44v5表达情况.结果胃癌患者术前PBL CD44v5含量较正常对照组明显增高(P＜0.01).有转移的胃癌患者PBL CD44v5含量明显高于无转移者(P＜0.01).术前PBL CD44v5含量与肿瘤大小、浸润深度、淋巴结转移及病理分期呈显著的正相关(r=0.486,P＜0.05).正常胃粘膜无CD44v5表达,胃癌组织CD44v5表达阳性率为69.7%,其表达与肿瘤浸润深度和淋巴结转移存在显著相关性.胃癌原发灶CD44v5表达阳性者其淋巴结转移阳性率显著高于阴性者.结论 CD44v5有望作为监测胃癌转移的生物学指标.应用FCM定量检测胃癌患者术前外周血CD44v5含量,对胃癌转移的诊断和进展的评价可能具有重要的临床意义.     

新辅助化疗联合同期放疗对直肠癌CD44v6表达的影响和意义

目的：探讨新辅助化疗联合同期放疗对直肠癌CD44v6表达的影响和意义。方法：采用免疫组化SP法测定36例研究组（术前接受化放疗）及36例对照组（术前未行放化疗）直肠癌患者癌组织、正常组织中CD44v6的表达。结果：两组72例患者正常直肠黏膜上皮细胞中CD44v6表达均阴性。研究组中CD44v6表达显著低于对照组（P〈0.05）。两组72例患者中侵润至浆膜层和有淋巴结转移的直肠癌组织CD44v6阳性表达率明显高于侵润至肌层和无淋巴结转移者（P〈0.05）。手术并发症两组比较差异无显著性（P〉0.05）。研究组保肛率80.6%（29/36）明显高于对照组55.6%（20/36）（P〈0.05）。结论：CD44v6在直肠癌的侵袭和转移中起重要作用,检测CD44v6的表达情况是判断直肠癌转移能力的重要指标。新辅助化疗联合同期放疗能有效降低直肠癌组织CD44v6表达水平,从而有效降低了直肠癌细胞的侵袭与转移;同时能使肿瘤降期,提高保肛率,手术并发症无增加。     

CD24mRNA和PDGF-D mRNA在结直肠癌组织中的表达及意义

目的检测CD24mRNA和PDGF-D mRNA在结直肠癌组织及切缘正常组织的表达情况,探讨两者与结直肠癌发生发展的关系。方法收集54例结直肠癌组织及其相应的切缘正常组织,用RT-PCR方法分别检测两种组织中CD24mR-NA和PDGF-D mRNA的表达水平,应用SPSS17.0统计学软件分析它们与临床病理之间的关系。结果 CD24mRNA和PDGF-D mRNA在结直肠癌组织中的表达水平高于切缘正常组织(0.8322±0.0856:0.2065±0.0871,0.8482±0.0692:0.2533±0.0716)。CD24mRNA的表达与结直肠癌的浸润程度有关(P0.05),与年龄、肿瘤的分化程度、Duke's分期、肿瘤大小等因素无关(P0.05)。PDGF-D mRNA的表达与年龄、肿瘤的分化程度、Dukes分期有关(P0.05),与结直肠癌的浸润程度、肿瘤大小因素无关(P0.05)。相关分析表明CD24mRNA和PDGF-D mRNA在结直肠癌组织中表达呈正相关(rs=0.383,P=0.004)。结论 CD24和PDGF-D在结直肠癌组织中均呈高表达,且与结直肠癌的发生发展密切相关,提示两者可能成为结直肠癌早期诊断和评价预后的新指标,并为结直肠癌的靶向治疗提供新思路。     

血清中可溶性CD44v6含量和组织中CD44v6蛋白表达研究

目的　研究胃癌患者外周血中sCD44v6含量及其组织中CD44v6蛋白表达 ,探讨sCD44v6含量 /CD44v6蛋白与临床病理参数之间的关系。方法　应用酶联免疫吸附试验 (ELISA)检测胃癌患者 (术前 )及其中部分术后及健康对照组血清中sCD44v6含量并以 (S P)免疫组织化学法测定相应组织中CD44v6蛋白的表达。结果　 70例胃癌患者血清中sCD44v6含量 (2 .15± 0 .78)μg/L明显高于 16例正常对照组 (1.18± 0 .43 ) μg/L、14例根治性手术后血清中sCD44v6含量(1.2 1± 0 .3 9) μg/L比术前 (2 .67± 0 .83 ) μg/L明显下降 (P <0 .0 1) ,而 6例非根治性手术后(3 .2 9± 0 .41) μg/L比术前 (3 .61± 0 .49) μg/L下降不明显 (P >0 .0 5 )。结论　胃癌患者外周血中sCD44v6含量及组织中CD44v6蛋白表达的变化与转移、临床分期、病理分期有关 ,sCD44v6含量升高可作为胃癌患者淋巴结转移 (尤其是早期转移 )的监测指标。     

结直肠癌患者血清可溶性CD26增高及其意义

目的评价血清可溶性CD2(6sCD26)对结直肠癌的诊断价值。方法收集我院59例结直肠癌患者、51例结直肠良性疾病患者和41例健康对照患者的血清,采用ELISA法检测血清中sCD26浓度。采用受试者工作曲线(ROC)法评价血清sCD26对结直肠癌的诊断价值,并采用logistic回归分析其对结直肠癌的关系是否独立于癌胚抗原(CEA)。结果结直肠癌患者血清sCD26水平较健康对照组和结直肠良性疾病组患者增高(P<0.01),但sCD26在Dukes不同分期间的差异无统计学意义(P=0.78)。sCD26诊断结直肠癌的曲线下面积为0.72〔95%可信区间(CI)为0.63～0.82,P<0.01〕,最佳诊断界值为526μg/L。sCD26的诊断敏感度和特异度分别为0.59(95%CI为0.48～0.72)和0.80(95%CI为0.67～0.90)。在包含了CEA的logistic回归模型中,sCD26阳性(≥526μg/L)的优势比为5.17(95%CI为1.72～15.53,P<0.01)。DukesA期结直肠癌患者sCD26较CEA具有更高的阳性率(P=0.03),但Dukes B、C和D期结直肠癌患者sCD26的阳性率均低于CEA(P<0.05)。结论sCD26对结直肠癌具有较高且独立于CEA的诊断价值。与CEA相比,sCD26更具有成为结直肠癌早期标志物的潜质。     

CD44v9和MMP-9在结直肠癌组织中表达的临床意义

目的研究CD44v9和基质金属蛋白酶-9(MMP-9)在结直肠癌和癌旁组织中表达的临床意义。方法采用RT-PCR方法分别检测46例结直肠癌及癌旁组织CD44v9及MMP-9的阳性表达情况。结果46例结直肠癌组织中CD44v9和MMP-9的阳性表达率分别是58.7%和82.6%,明显高于癌旁组织(58.7%和47.8%),两者比较差异均有统计学意义(P<0.001)。CD44v9和MMP-9在结直肠癌组织的阳性表达率与肿瘤的大小、分化高低、浸润深度、临床分期及淋巴结转移相关,而且两者在结直肠癌中的表达呈正相关。结论CD44v9和MMP-9与结直肠癌侵袭和转移性有关,可作为预测肿瘤转移潜能的指标。     

The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer

CD44 variant 6 (CD44 v6) is well known as a useful marker of tumor progression; however, its relationship to prognosis has not yet been elucidated. In this study, we investigated the expression of CD44 v6 in colorectal cancer to analyze its relationship to hepatic metastasis as well as to prognosis. Tumor tissues were obtained from 42 patients with colorectal cancer who underwent curative resection with follow-up periods ranging from 5.9 to 71.3 months. There were 21 patients (50%) whose tumors were positive for CD44 v6, with no significant difference between colon and rectal cancer. CD44 v6 staining was significantly related to Dukes' classification as well as to hepatic metastasis. The 5-year survival rate was significantly higher in patients with CD44 v6 negative cancer (84%) than in those with CD44 v6 positive cancer (31%). Thus, we concluded that CD44 v6 could be a reliable prognostic indicator, as well as a predictor of metastatic potential after curative surgery for colorectal cancer.     

Serum CD10 is associated with liver metastasis in colorectal cancer

Introduction

Colorectal cancer (CRC) is the third leading cause of cancer death in Japan. CD10 expression is closely associated with liver metastasis. In the present study, we explored the possibility of serum CD10 as a marker of liver metastasis in CRC.

Methodology

BALB/c mouse with subcutaneous tumor of syngeneic CT26 CRC cells were examined serum CD10. In 84 CRC patients and patients undergoing hemodialysis, serum CD10 was examined. CD10 concentration was measured by enzyme-linked immunosorbent assay.

Results

In a mouse subcutaneous tumor model, serum CD10 correlated with the weight of the tumors. Serum CD10 was examined in 84 patients with CRC. The serum levels of CD10 were higher in patients with more advanced cancer stages. Patients with liver metastasis showed the highest levels of serum CD10 among all patients. Importantly, patients with high serum CD10 levels had metachronous liver metastasis. Healthy volunteers showed low levels of CD10; however, serum CD10 levels in patients undergoing hemodialysis showed levels as high as those with stage II and III CRC. A cutoff of serum CD10 set to >1000 pg/mL showed 70% sensitivity and 93% specificity for liver metastasis in CRC. This cutoff included all cases of metachronous liver metastasis.

Conclusions

With the exclusion of mimicking factors, serum CD10 levels might serve as a useful marker of synchronous and metachronous liver metastasis in CRC.     

肿瘤干细胞表型CD44和CD24在乳腺癌骨转移模型骨髓中的表达及意义

目的 探讨人乳腺癌细胞转移到人骨的乳腺癌骨转移小鼠模型中骨髓肿瘤干细胞表型CD44和CD24的表达及其意义.方法 50只SCID小鼠随机分成实验组和对照组,其中实验组鼠背部植入人骨后随机均分3亚组:A组(MDA-MB-231干细胞亚群1×105个/只)、B组(同A组细胞1×106个/只)和C组(MDA-MB-231亲代细胞1×106个/只);对照组设为D组(阳性对照,未植入人骨,同C组细胞直接注射)、E组(阴性对照,植入人骨,生理盐水注射).各组8周后取人骨、鼠骨等行常规HE染色及CK、CD44、CD24、CXCR4、OPN免疫组织化学标记.Real-time PCR检测CD44、CXCR4、OPN的mRNA水平.结果 B组骨转移率最高(77.8%,P＜0.05).B组中人骨转移灶CD44、CXCR4、OPN抗原表达高于C、D组骨中的表达(均有P＜0.05);CD24抗原则在A、B组人骨转移灶中低表达与C、D组骨中的高表达无统计学意义(P＞0.05).B组CD44mRNA表达水平是C组的15.2倍、D组的21.1倍;B组CXCR4mRNA表达水平是C组8.4倍、D组28.4倍;B组OPN-mRNA表达水平是C组4.8倍、D组11.6倍;而B组CD24的mRNA表达显著低于C、D组(均为30%).结论 利用MDA-MB-231肿瘤干细胞亚群(CD44+/CD24-)可制备高转移率的"人源性"乳腺癌骨转移模型,其机制可能与CD44高表达有关.骨转移相关基因CXCR4、OPN转录上调可能参与其过程.     

结直肠癌患者中性粒细胞淋巴细胞比值和T淋巴细胞CD69变化的意义

目的:探讨结直肠癌患者术前外周血中T淋巴细胞CD69、中性粒细胞淋巴细胞比值(NLR)变化的意义.方法:选取2016年5月—2018年12月我院收治的126例结直肠癌患者(病例组)、120例结肠息肉患者(对照组);检测两组的术前外周血中T淋巴细胞CD69、NLR,分析不同临床病理学特征的结直肠癌患者T淋巴细胞CD69、...     

OPN和CD44V6在结直肠癌和结直肠腺瘤中的表达及意义

目的 探讨骨桥蛋白（OPN）和CD44拼接变异体6（CD44v6）在结直肠癌和结直肠腺瘤中的表达及意义.方法采用免疫组化法检测72例结直肠癌标本、60例结直肠腺瘤标本中OPN和CD44v6的阳性表达情况,分析两者与结直肠癌临床病理特征的关系.结果结直肠癌、腺瘤、正常组织OPN表达阳性率分别为81.9%、66.7%、2.8%,CD44v6表达阳性率分别为75.0%、56.7%、2.8%,各组OPN和CD44v6的表达阳性率差异均有统计学意义（P＜0.05）.OPN的表达与肿瘤浸润深度、分化状态、有无淋巴结转移存在相关性（P＜0.05）,CD44v6的表达与肿瘤浸润深度、有无淋巴结转移存在相关性（P＜0.05）.OPN与CD44v6表达存在显著正相关关系（r=0.517,P＜0.05）.结论 OPN、CD44v6的表达与结直肠腺瘤-癌的转化及结直肠癌细胞的侵袭力等密切相关,通过检测两者水平可对结直肠癌的早期预防、诊断及预后评估提供重要依据.     

LN、CD105及CD44V6在大肠癌组织中的表达及临床意义

为观察大肠癌手术前后血清层粘连蛋白（LN）含量的变化和大肠癌组织中LN与血清LN的相关性,研究大肠癌组织中CD105及黏附分子CD44拼接变异体V6（CD44V6）的表达及意义,探讨大肠癌组织中LN、CD105和CD44V6与大肠癌生物学行为之间的关系,我们利用放射免疫技术（RIA）对血清和大肠癌灶组织、大肠正常组织匀浆中LN进行测定,采用免疫组化SP法检测大肠癌灶组织、大肠正常组织中CD105和CD44V6的表达情况。结果显示：（1）大肠癌组根治性术后血清LN含量明显低于术前和大肠良性疾病组（P〈0．05）;（2）LN在癌灶组织中的含量明显高于癌灶远隔组织（P〈0．05）,癌灶组织与血清中的LN含量呈直线正相关（r=0．978）;（3）CD105在大肠癌组织中的表达明显高于大肠正常组织（P〈0．05）。CD44V6在大肠癌组织和大肠正常组织中的阳性表达率分别为67．6％和33．8％（P〈0．05）。CD44V6阳性组MVD值及组织LN含量明显高于CD44V6阴性组（P〈0．05）。结果表明,血清LN检测对大肠癌的诊断、防治、手术效果评估及术后动态观察肿瘤的复发转移具有临床意义。CD105和CD44V6高表达与肿瘤的发生、发展有密切关系,MVD、LN与CD44V6表达相关。     

CD105在结直肠癌中的表达及其临床意义

目的探讨CD105在结直肠癌中的表达及其作为肿瘤新生血管标记物的临床价值。方法采用鼠抗人CD105单克隆抗体(MAb),应用免疫组织化学技术检测48例结直肠癌手术切除标本及48例对照组织的微血管密度(MVD),并以Ⅷ因子相关抗原(F-8RAg)及血管内皮生长因子(VEGF)的表达作为对照研究。结果(1)MVD及VEGF在结直肠癌组织与对照组织间表达的差异具有非常显著性意义(P<0.001,P<0.01);(2)以CD105和F-8RAg测得的MVD差异具有非常显著性意义(P<0.001);(3)VEGF在结直肠癌的表达与CD105的表达呈显著正相关(P<0.01),而与F-8RAg的表达无关(P>0.05)。结论CD105在结直肠癌组织新生血管有良好表达,可以作为结直肠癌新生血管有价值的标志物。以CD105测得的MVD可以被认为是与肿瘤生长、转移及预后有关的一种重要指标。     

Evaluation of clinicopathological factors and the correlation between the adhesion molecule CD44 variant 9 expression and pulmonary metastases from colorectal cancers

Pulmonary metastases occur in 3% to 8% of all cases of colorectal cancers. Therefore, we evaluated prognostic factors and examined the correlation between the expression of adhesion molecule CD44 variant 9 and the pulmonary metastasis from colorectal cancer. Of 512 patients with colorectal cancers, clinicopathological findings, prognoses, and prognostic factors were evaluated in 42 patients with pulmonary metastases (8%), together with the expression of adhesion molecule CD44 variant 9 by immunohistochemical staining with monoclonal antibody prepared in our department. It was found that the presence or absence of extrapulmonary metastasis, treatment by pulmonary resection, and serum carcinoembryonic antigen levels were prognostic factors. The 5-year survival rate was 35% in patients who underwent pulmonary resection. In addition, adhesion molecule CD44 variant 9 was expressed in the primary colorectal cancers in 89 (42%) of 213 patients without hematogenous metastases and 23 (88%) of 26 patients with pulmonary metastases. Therefore, the rate of CD44 variant 9 expression in the primary colorectal cancer tissues was significantly higher in patients with pulmonary metastases from colorectal cancers. Among patients with pulmonary metastases from colorectal cancers, long-term survival was achieved in those without extrapulmonary metastases, because metastatic tumors in the lungs were completely removed by pulmonary resection. In addition, the abnormal expression of adhesion molecule CD44 variant 9 in the primary colorectal cancer is partly responsible for pulmonary metastasis.